Comparison of inhaled heparin/N-acetylcysteine, N-acetylcystein alone, and placepo for the treatment of COVID-19 patients

Phase 3

Recruiting

• Conditions: COVID-19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20201210049672N1
• Lead Sponsor: Vice-Chancellery for Research Hormozgan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Definitive COVID-19 diagnosis based on PCR results
Admission to the intensive care unit

Exclusion Criteria

Hypersensitivity to heparin and N-acetyl cysteine
Coagulopathies

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intensive care unit length of stay. Timepoint: At the end of the study. Method of measurement: Checklist.

Secondary Outcome Measures

Name	Time	Method
Tracheal intubation requirement. Timepoint: Any time during the study. Method of measurement: Checklist.;Mechanical ventilation requirement. Timepoint: Any time during the study. Method of measurement: Checklist.;Death. Timepoint: Any time during the study. Method of measurement: Checklist.